"The Report Simponi
(golimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to
2023 provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
Description
Simponi (golimumab)
(Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints. It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
J&Js Simponi (golimumab)
is a fully-human IgG1 mAb specific for TNFa. It inhibits TNFa
activity, thereby blocking the inflammatory activity of this cytokine
and downstream reactions. Simponi is approved for patients with
moderate to severe, active RA, and is typically prescribed in
conjunction with MTX as a second line of therapy in patients who have
failed treatment with another anti-TNF agent, or who have had an
unsatisfactory response to MTX.
View
Full Report at http://www.marketresearchreports.biz/analysis/247128
Scope
- Overview of Rheumatoid
Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on
Simponi (golimumab) including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for Simponi
(golimumab) for the top 8 countries from 2013 to 2023.
- Sales information covered
for the US, France, Germany, Italy, Spain, the UK, Japan and
Australia.
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return.
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid Arthritis.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential.
- Make more informed business
decisions from insightful and in-depth analysis of Simponi
(golimumab) performance.
- Obtain sales forecast for
Simponi (golimumab) from 2013-2023 in top 8 countries (the US,
France, Germany, Italy, Spain, the UK and Japan and Australia).
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports
13
3 Disease Overview 14
3.1 Etiology and
Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 19
3.3 Prognosis 20
3.4 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment
Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines 23
4.1.3 Leading Prescribed Drugs
for the Treatment of RA 33
4.1.4 Clinical Practice 34
5 Competitive Assessment 40
5.1 Overview 40
6 Simponi (golimumab) 42
6.1 Overview 42
6.2 Efficacy 44
6.3 Safety 45
6.4 SWOT Analysis 46
6.5 Forecast 47
7 Appendix 48
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment